EP0515535A4 - Angiotensin ii antagonists incorporating a substituted benzyl element - Google Patents

Angiotensin ii antagonists incorporating a substituted benzyl element

Info

Publication number
EP0515535A4
EP0515535A4 EP91905007A EP91905007A EP0515535A4 EP 0515535 A4 EP0515535 A4 EP 0515535A4 EP 91905007 A EP91905007 A EP 91905007A EP 91905007 A EP91905007 A EP 91905007A EP 0515535 A4 EP0515535 A4 EP 0515535A4
Authority
EP
European Patent Office
Prior art keywords
angiotensin
substituted benzyl
antagonists incorporating
benzyl element
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91905007A
Other versions
EP0515535A1 (en
Inventor
William J Greenlee
Arthur A Patchett
David Hangauer
Thomas Walsh
Kenneth J Fitch
Ralph A Rivero
Daljit S Dhanoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0515535A1 publication Critical patent/EP0515535A1/en
Publication of EP0515535A4 publication Critical patent/EP0515535A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP91905007A 1990-02-13 1991-02-11 Angiotensin ii antagonists incorporating a substituted benzyl element Withdrawn EP0515535A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47978690A 1990-02-13 1990-02-13
US479786 1990-02-13

Publications (2)

Publication Number Publication Date
EP0515535A1 EP0515535A1 (en) 1992-12-02
EP0515535A4 true EP0515535A4 (en) 1996-01-17

Family

ID=23905431

Family Applications (2)

Application Number Title Priority Date Filing Date
EP91905007A Withdrawn EP0515535A4 (en) 1990-02-13 1991-02-11 Angiotensin ii antagonists incorporating a substituted benzyl element
EP91905733A Withdrawn EP0517812A4 (en) 1990-02-13 1991-02-11 Angiotensin ii antagonists incorporating a substituted benzyl element

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP91905733A Withdrawn EP0517812A4 (en) 1990-02-13 1991-02-11 Angiotensin ii antagonists incorporating a substituted benzyl element

Country Status (4)

Country Link
EP (2) EP0515535A4 (en)
JP (2) JPH05504969A (en)
CA (2) CA2075637A1 (en)
WO (2) WO1991011999A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
US5240938A (en) * 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
US5177095A (en) * 1990-02-13 1993-01-05 Merck & Co., Inc. Triazole angiotensin II antagonists incorporating a substituted benzyl element
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
DE4224133A1 (en) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
EP0531874A1 (en) * 1991-09-10 1993-03-17 Tanabe Seiyaku Co., Ltd. Imidazopyridine derivatives and process for preparation thereof
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9121727D0 (en) * 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
TW226375B (en) * 1991-10-24 1994-07-11 American Home Prod
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
DE4309968A1 (en) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamides of heterocyclic substituted phenylacetic acid derivatives
JP3269658B2 (en) 1992-06-02 2002-03-25 エーザイ株式会社 Phenol derivatives
AU4348593A (en) * 1992-06-25 1994-01-24 Zeneca Limited Chromanderivatives as angiotensin ii antagonists
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
SK2895A3 (en) * 1992-07-10 1995-07-11 Boots Co Plc Substituted 3-cyclobutene-1,2-diones, method of their preparation and pharmaceutical agents which containing thereof
DE4302956A1 (en) * 1993-02-03 1994-08-04 Bayer Ag Substituted imidazo (4,5-b) pyridines and benzimidazoles
US5300668A (en) * 1993-03-10 1994-04-05 Pfizer Inc. Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
AP9400651A0 (en) * 1993-07-15 1995-12-30 Pfizer Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists.
DE4327256A1 (en) * 1993-08-13 1995-02-16 Bayer Ag Sulfonylbenzyl-substituted benzimidazoles, process for their preparation and their use in medicaments
ES2079315B1 (en) * 1994-02-24 1996-10-16 Uriach & Cia Sa J NEW IMIDAZOPIRIDINES.
CA2184891C (en) * 1994-03-08 2000-09-26 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
CN1176918C (en) * 1994-04-06 2004-11-24 盐野义制药株式会社 Intermediates of Novel α-Substituted Phenylacetic Acid Derivatives with Agricultural Fungicidal Activity
USD357459S (en) 1994-05-04 1995-04-18 Woods Industries, Inc. Male plug housing having a circuit breaker
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
CN1192696A (en) * 1995-06-07 1998-09-09 G·D·瑟尔公司 Combination therapy of spironolactone and angiotensin Ⅱ antagonists for the treatment of congestive heart failure
GB9716446D0 (en) * 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
PT1094816E (en) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
EP1503993A4 (en) 2002-05-09 2006-05-03 Cytokinetics Inc Compounds, methods and compositions
JP2005530785A (en) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
EP1556357A4 (en) 2002-06-14 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2006501306A (en) 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
KR20060041309A (en) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
GB0328295D0 (en) * 2003-12-05 2004-01-07 Muscagen Ltd Therapeutic compounds
JP2007513154A (en) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
JP2007527911A (en) * 2004-03-08 2007-10-04 ワイス Ion channel modulator
AU2006290205B2 (en) 2005-09-14 2012-12-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20120046308A1 (en) 2009-05-29 2012-02-23 Kowa Company, Ltd. Novel alpha-phenoxybenzeneacetic acid derivative and pharmaceutical preparation comprising same
WO2011138657A1 (en) * 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING
TWI663159B (en) * 2013-12-10 2019-06-21 美商健臻公司 Tropomyosin-related kinase (trk) inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US4420487A (en) * 1978-04-10 1983-12-13 The Purdue Frederick Company Diuretic and antihypertensive benzimidazoles
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
US4728741A (en) * 1985-01-08 1988-03-01 Smithkline Beckman Corporation 1-substituted-2-mercapto benzimidazole compounds and intermediates
US4772600A (en) * 1986-06-09 1988-09-20 A. H. Robins Company, Inc. Fused imidazoheterocyclic compounds and pharmaceutical compositions
EP0260621A3 (en) * 1986-09-18 1989-03-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft 3-aryl uracil-enol ethers and their use as herbicides
JPH07107056B2 (en) * 1987-01-30 1995-11-15 日清製粉株式会社 4 (3H) -quinazolinone derivative, method for producing the same and antiulcer agent containing the same
AU2328188A (en) * 1987-09-23 1989-04-18 Ciba-Geigy Ag Heterocyclic compounds
GB8904174D0 (en) * 1989-02-23 1989-04-05 British Bio Technology Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9112001A1 *

Also Published As

Publication number Publication date
JPH05504969A (en) 1993-07-29
CA2075627A1 (en) 1991-08-14
EP0517812A4 (en) 1995-10-18
JPH05503530A (en) 1993-06-10
EP0517812A1 (en) 1992-12-16
CA2075637A1 (en) 1991-08-14
EP0515535A1 (en) 1992-12-02
WO1991011999A1 (en) 1991-08-22
WO1991012001A1 (en) 1991-08-22

Similar Documents

Publication Publication Date Title
EP0517812A4 (en) Angiotensin ii antagonists incorporating a substituted benzyl element
EP0515546A4 (en) Triazole angiotensin ii antagonists incorporating a substituted benzyl element
AU8374491A (en) Angiotensin II receptor antagonists
IL105877A0 (en) Angiotensin ii antagonists
FI932518A7 (en) Angiotensin II antagonists
EP0543491A3 (en) Angiotensin ii antagonists having a substituted 1,3-benzodioxolering or 1,3-benzodithiolering
EP0586613A4 (en) Bradykinin antagonists
HU913074D0 (en) Fibrinogenic receptor antagonists
GB2272376B (en) A multifunction multielectrode device
PH31071A (en) Substituted pyrridopyrimidines useful antgiotensinII antagonists.
AU3276293A (en) Angiotensin II receptor antagonists
ZA916711B (en) Bradykinin antagonists
GB9317760D0 (en) Angiotensin ii antagonist
EP0515548A4 (en) Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
EP0505111A3 (en) Angiotensin ii antagonists incorporating a substituted imidazo (1,2-b)(1,2,4) triazole
GB9317758D0 (en) Angiotensin ii antagonist
DE69204920D1 (en) Angiotensin II antagonists.
EP0546449A3 (en) Benzofuranderivatives as angiotensin ii antagonists
IL110239A0 (en) Azacyclic - heterocyclic compounds as angiotensin II receptor antagonists
GB9303632D0 (en) Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element
GB9216958D0 (en) Angiotensin ii antagonists incorporating a substituted benzyl element
GB9217033D0 (en) Angiotensin ii antagonists incorporating a substituted benzyl element
ZA931146B (en) A novel 5-ht3-receptor antagonist.
GB9217034D0 (en) Triazole angiotensin ii antagonists incorporating a substituted benzyl element
ZA917693B (en) Fibrinogen receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920808

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19951201

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RBV Designated contracting states (corrected)

Designated state(s): CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19970211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980901